Search results
Results from the WOW.Com Content Network
Onychomycosis occurs in about 10 percent of the adult population, [2] with older people more frequently affected. [2] Males are affected more often than females. [3] Onychomycosis represents about half of nail disease. [2] It was first determined to be the result of a fungal infection in 1853 by Georg Meissner. [6]
It may appear as loss of nail palate translucency, discoloration, and subungual hyperkeratosis. Complications include pain, distal onycholysis, subungual bleeding, subungual ulceration, and onychomycosis. Treatment includes debridement of the nail plate, urea pastes, electric drills, nail avulsion, and chemical or surgical matricectomy.
Efinaconazole, sold under the brand name Jublia among others, is a triazole antifungal medication. It is approved for use in the United States, Canada, and Japan as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail).
Nail inspection can give hints to the internal condition of the body as well. Nail disease can be very subtle and should be evaluated by a dermatologist with a focus in this particular area of medicine. A nail technician may be the first to note a subtle change in nail health. [2] [3] [4]
Cleaning under the nail is not recommended as this only serves to separate the nail further. Bandages are also to be avoided. [11] When kept dry and away from further trauma, the nail will reattach from the base upward (i.e., from proximal to distal). The aim of treatment is also to eliminate onychomycosis that is a major cause of onycholysis.
For premium support please call: 800-290-4726 more ways to reach us
Treatment is generally performed using antifungal medicines, usually in the form of a cream or by mouth or injection, depending on the specific infection and its extent. [15] Some require surgically cutting out infected tissue. [3] Fungal infections have a world-wide distribution and are common, affecting more than one billion people every year ...
Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” [1] Tavaborole was approved by the US FDA in July ...